With the availability of SARS-CoV-2/COVID-19 vaccines, a crucial challenge is the prioritisation of groups of individuals to receive vaccines that will be in limited supply for some time.1

Several clinical reports have described greater morbidity and mortality from COVID-19 in people with diabetes, often accompanied by obesity. Most of this information is from individuals with type 2 diabetes, with less known about the risk in type 1 diabetes, a phenotypically distinct disorder. Experts have cautioned against extrapolating from studies of type 2 diabetes to individuals with type 1 diabetes.2

In the USA, the Centers for Disease Control and Prevention (CDC) currently categorise type 1 and type 2 diabetes differently in terms of risk for severe illness from COVID-19, with people with type 2 diabetes considered “at increased risk for severe illness” and those with type 1 diabetes categorised as “might be at increased risk”.3

Credit: Amanda Mills CDC

Read more at Lancet…